A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)

• Published in: Journal of gynecologic oncology Vol. 36; no. 3; pp. e35 - 8
• Main Authors: Lee, Yong Jae, Lee, Yoo-Young, Park, Jeong-Yeol, Cho, Hyun-Woong, Lim, Myong Cheol, Kim, Mi Kyung, Lee, Jong-Min, Lee, Jung-Yun
• Format: Journal Article
• Language: English
• Published: Korea (South) Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 01.05.2025; 대한부인종양학회
• Subjects: Aged; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Brain Neoplasms; Clinical Trial Protocol; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; DNA Mismatch Repair; Endometrial Neoplasms - drug therapy; Endometrial Neoplasms - genetics; Endometrial Neoplasms - immunology; Endometrial Neoplasms - pathology; Endometrial Neoplasms - surgery; Female; Humans; Immune Checkpoint Inhibitors - administration & dosage; Immune Checkpoint Inhibitors - adverse effects; Immune Checkpoint Inhibitors - therapeutic use; Microsatellite Instability; Middle Aged; Neoplastic Syndromes, Hereditary; Nivolumab - administration & dosage; Nivolumab - adverse effects; Nivolumab - therapeutic use; Programmed Cell Death 1 Receptor - antagonists & inhibitors; 산부인과학; Endometrial Cancer; PD-L1 Inhibitor; Mismatch Repair Deficiency

Mismatch repair deficient (MMRd) tumors are known to be highly immunogenic and of great interest for immune checkpoint inhibitor. However, there is no data about the complete response (CR) rate of programmed cell death protein 1 (PD-1) blockade and surgery in subjects with MMRd surgically resectable...